Precision BioSciences Inc (DTIL)vsVertex Pharmaceuticals Inc (VRTX)
DTIL
Precision BioSciences Inc
$6.26
+1.29%
HEALTHCARE · Cap: $171.68M
VRTX
Vertex Pharmaceuticals Inc
$522.81
-0.74%
HEALTHCARE · Cap: $130.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 27837% more annual revenue ($12.59B vs $45.05M). VRTX leads profitability with a 35.0% profit margin vs -117.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
DTIL
Avoid33
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$13.23
Current Price
$6.26
$6.97 discount
Margin of Safety
+45.0%
Fair Value
$957.59
Current Price
$522.81
$434.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.25 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 33/100), backed by strong 35.0% margins and 12.5% revenue growth. DTIL offers better value entry with a 69.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?